BioXcel Therapeutics, Inc.
BTAIQ
$0.05
$0.009.56%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 182.00K | 206.00K | 256.00K | 98.00K | 120.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 182.00K | 206.00K | 256.00K | 98.00K | 120.00K |
| Cost of Revenue | 22.00K | 283.00K | 32.00K | 11.00K | 107.00K |
| Gross Profit | 160.00K | -77.00K | 224.00K | 87.00K | 13.00K |
| SG&A Expenses | 7.19M | 7.19M | 3.81M | 5.38M | 5.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.38M | 10.43M | 10.54M | 14.13M | 15.97M |
| Operating Income | -10.19M | -10.22M | -10.28M | -14.03M | -15.85M |
| Income Before Tax | -14.71M | -12.69M | -12.55M | -30.91M | -19.19M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.71M | -12.69M | -12.55M | -30.91M | -19.19M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.71M | -12.69M | -12.55M | -30.91M | -19.19M |
| EBIT | -10.19M | -10.22M | -10.28M | -14.03M | -15.85M |
| EBITDA | -10.18M | -10.17M | -10.21M | -13.96M | -15.78M |
| EPS Basic | -0.49 | -0.54 | -0.57 | -2.18 | -2.45 |
| Normalized Basic EPS | -0.30 | -0.34 | -0.36 | -1.35 | -1.53 |
| EPS Diluted | -0.49 | -0.54 | -0.57 | -2.18 | -2.45 |
| Normalized Diluted EPS | -0.30 | -0.34 | -0.36 | -1.35 | -1.53 |
| Average Basic Shares Outstanding | 30.30M | 23.57M | 21.86M | 14.20M | 7.84M |
| Average Diluted Shares Outstanding | 30.30M | 23.57M | 21.86M | 14.20M | 7.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |